Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual agonist that hits both the GIP and GLP-1 receptors. Semaglutide is sold as Ozempic and Rybelsus (diabetes) and Wegovy (weight); tirzepatide is sold as Mounjaro (diabetes) and Zepbound (weight and sleep apnea with obesity). On average, tirzepatide produced higher weight loss in trials (~20% vs ~15% for semaglutide 2.4 mg) and beat semaglutide in a head-to-head diabetes trial. Both share the GLP-1 GI side effects, and the right choice is individual — decided with a clinician.
Key takeaways
- Semaglutide = GLP-1 agonist (one receptor); tirzepatide = dual GIP/GLP-1 agonist (two receptors).
- Brand map: semaglutide → Ozempic, Rybelsus, Wegovy; tirzepatide → Mounjaro, Zepbound.
- Average trial weight loss is higher for tirzepatide (~20%) than semaglutide 2.4 mg (~15%); tirzepatide also won a head-to-head diabetes trial.
- Both carry the same GLP-1 GI side-effect profile; "better" depends on tolerability, coverage and cost.
The core difference: one receptor vs two
Both drugs mimic gut hormones that your body releases after eating — hormones that tell your pancreas to release insulin, slow how fast your stomach empties, and signal fullness to your brain. That's the shared GLP-1 backbone, and it's why both quiet appetite and "food noise." You can read the basics in our what is GLP-1 explainer.
Semaglutide activates the GLP-1 receptor. Tirzepatide activates GLP-1 and a second receptor, GIP (glucose-dependent insulinotropic polypeptide). That extra target is the structural headline of the whole comparison: adding GIP action is the widely cited reason tirzepatide tends to produce larger average reductions in both blood sugar and body weight. It's not that semaglutide is weak — it's that tirzepatide brings a second lever.
The brand map
One of the most confusing parts of this whole space is that each molecule wears several names. Here's the untangled version:
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Maker | Novo Nordisk | Eli Lilly |
| Diabetes brands | Ozempic (injection), Rybelsus (oral) | Mounjaro (injection) |
| Weight-management brand | Wegovy | Zepbound |
| Other approvals | Wegovy: reducing cardiovascular risk | Zepbound: obstructive sleep apnea with obesity |
| Average weight loss (trials) | ~15% (semaglutide 2.4 mg, STEP) | ~20% at higher doses (SURMOUNT) |
| Dosing | Once-weekly injection (Rybelsus is a daily pill) | Once-weekly injection |
So when someone asks "Is Ozempic the same as Wegovy?" — yes, both are semaglutide. "Is Mounjaro the same as Zepbound?" — yes, both are tirzepatide. The molecule stays the same within each column; only the approved use, dose and branding change. Our medications guide lays out the full lineup.
Is tirzepatide stronger than semaglutide?
By the trial numbers, on average — yes. Tirzepatide averaged roughly 20% body-weight loss at higher doses in its SURMOUNT weight-management program, versus about 15% for semaglutide 2.4 mg in the STEP program. And in diabetes, the head-to-head SURPASS-2 trial found tirzepatide produced greater A1c and weight reductions than semaglutide. Two different lines of evidence point the same direction.
But "stronger" deserves an asterisk. These are group averages, not personal guarantees — individual response varies enormously, and factors like diet, activity, sleep and staying on treatment shape the real outcome. A drug you can't tolerate or afford won't outperform one you can stick with. Use our weight-loss calculator to translate averages into a realistic personal range rather than fixating on the headline percentage.
Side effects and tolerability
Because both share the GLP-1 mechanism, they share the side-effect profile: nausea, constipation, diarrhea and reduced appetite, most pronounced when starting or stepping up a dose and usually easing over time. Our side-effects guide covers how to manage each. Tirzepatide's additional GIP activity means some people tolerate one better than the other, but there's no universal "gentler" molecule — it's individual.
Which is better, semaglutide or tirzepatide?
- Prioritizing average effect? Tirzepatide leads the trial numbers for both weight and blood sugar.
- Want an oral option? Semaglutide has a daily pill form (Rybelsus) for diabetes; tirzepatide is injection-only.
- Have a specific condition? Wegovy's cardiovascular-risk approval or Zepbound's sleep-apnea approval may tip the balance.
- Cost or coverage is the barrier? Whichever your plan approves for your diagnosis is often the practical answer.
This is general education, not a recommendation. Both molecules are effective, both are prescription-only, and the right one is decided with a clinician who knows your history, tolerability and coverage.
Frequently asked questions
What's the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist — it activates a single gut-hormone receptor. Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors. Both slow gastric emptying and reduce appetite, but tirzepatide's added GIP action is the structural reason it tends to average higher weight loss in trials.
Is tirzepatide stronger than semaglutide?
On average, tirzepatide produced greater weight loss (around 20% at higher doses) than semaglutide 2.4 mg (about 15%) in their respective trials, and it outperformed semaglutide in a head-to-head diabetes trial. But "stronger" is an average across groups; individual response, tolerability, cost and coverage all matter, and a clinician decides what's appropriate.
Which is better, semaglutide or tirzepatide?
There's no single winner for everyone. Tirzepatide leads on average trial results, but the better choice depends on tolerability, insurance coverage, cost, and your medical history. Both share the GLP-1 gastrointestinal side-effect profile. The decision is individual and made with a clinician; this is general education.
What brands are semaglutide and tirzepatide sold under?
Semaglutide is sold as Ozempic and Rybelsus (for type 2 diabetes) and Wegovy (for weight management). Tirzepatide is sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight management and obstructive sleep apnea with obesity). The molecule is the same across the brands of each drug; the difference is the approved use and dose.
Do semaglutide and tirzepatide have the same side effects?
Both share the typical GLP-1 gastrointestinal side effects — nausea, constipation, diarrhea and reduced appetite — usually most noticeable when starting or increasing the dose. Because tirzepatide also acts on the GIP receptor, individual tolerability can vary between the two, but neither is universally gentler. Discuss side effects with your clinician.
Sources & further reading
- U.S. Food & Drug Administration — prescribing information for semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound).
- SURPASS-2 trial, New England Journal of Medicine (2021) — tirzepatide vs semaglutide in type 2 diabetes.
- STEP (semaglutide 2.4 mg) and SURMOUNT (tirzepatide) clinical trial programs — published weight-management results.